Legal Raw Anabolic Steroid Powders & Semi-finishedLiquidsTrustful Supplier 

About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsAnti-estrogen Steroids

CAS 107868-30-4 Exemestane Anti-estrogen Steroids for ER-positive Breast Ccancer

Just want to let you know my order has arrived and this has been excellent service! It has been a pleasure, will be messaging you in the future!

—— Eduardo

Everything looks, smells, tastes and melts as they should. I am thinking I have you a very legit source.

—— Jason

Wa, amazing packing!!! I have never seen before, speedy delivery also, new order comes at the end of this week.

—— Peter

I'm Online Chat Now

CAS 107868-30-4 Exemestane Anti-estrogen Steroids for ER-positive Breast Ccancer

China CAS 107868-30-4  Exemestane Anti-estrogen Steroids for ER-positive Breast Ccancer supplier

Large Image :  CAS 107868-30-4 Exemestane Anti-estrogen Steroids for ER-positive Breast Ccancer

Product Details:

Place of Origin: China
Brand Name: Grand Uni or OEM
Certification: ISO9001
Model Number: CAS:107868-30-4

Payment & Shipping Terms:

Minimum Order Quantity: 10grams
Price: Negotiation
Delivery Time: 5~7 DAYS
Payment Terms: , MoneyGram, T/T
Supply Ability: 500KG PER WEEK
Contact Now
Detailed Product Description
Assay: 99% Min CAS: 107868-30-4
APPERANCE: White To Light Yellow Crystal Powder MF: C20H24O2
MW: 296.4 Name: Synonyms: Aromasin (exemestane)
High Light:

anabolic steroid hormones


medicine steroids


Hot sell Exemestane 107868-30-4 

  1. Synonyms: Aromasin (exemestane)
  2. Sale Specification:
  3. Quality standard: USP30
  4. Assay: 99% min.
  5. Chemical Properties: white to light yellow crystal powder 
  6. CAS: 107868-30-4 
  7. MF: C20H24O2 
  8. MW: 296.4 
  9. Categories: Active Pharmaceutical Ingredient; Antineoplastic (Hormonal); Steroids mp  155.13°C
  10. Packing: foil bag or tin.

Exemestane, FCE-24304, (trade name Aromasin) is a drug used to treat breast cancer. It is a member of the class of drugs known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be called estrogen-responsive, hormonally-responsive, or hormone-receptor-positive. Aromatase is anenzyme that synthesizes estrogen. Aromatase inhibitors block the synthesis of estrogen. This lowers the estrogen level, and slows the growth of cancers.

Exemestane is an oral steroidal aromatase inhibitor that is used in ER-positive breast cancer in addition to surgery and/or radiation in post-menopausal women.

The main source of estrogen is the ovaries in premenopausal women, while in post-menopausal women most of the body's estrogen is produced via the conversion of androgens into estrogen by the aromatase enzyme in the peripheral tissues (i.e. adipose tissue like that of the breast) and a number of sites in the brain. Estrogen is produced locally via the actions of the aromatase enzyme in these peripheral tissues where it acts locally. Any circulating estrogen in post-menopausal women as well as men is the result of estrogen escaping local metabolism and entering the circulatory system.

Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its inactivation, an effect also known as "suicide inhibition." By being structurally similar to enzyme targets, Exemestane permanently binds to the enzymes, preventing them from converting androgen into estrogen.

The estrogen suppression rate for exemestane varies from 35% for estradiol (E2) to 70% for estrone (E1).


Exemestane is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to it for completion of a total of five consecutive years of adjuvant hormonal therapy.US FDA approval was in October 2005.

Exemestane is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed followingtamoxifen therapy.

A Phase III trial has been reported which concluded that the use of exemestane in postmenopausal women at an increased risk for breast cancer reduced the incidence of invasive breast cancer. In 4,560 women, after 35 months, the administration of exemestane at a dose of 25 mg/day resulted in a 65% reduction in the risk of breast cancer compared with placebo; annual incidence rates were 0.19% and 0.55%, respectively

Contact Details

Contact Person: louis

Send your inquiry directly to us (0 / 3000)